Antiplatelet therapy prasugrel: a novel platelet ADP P2Y12 receptor antagonist.
Mousa
Shaker A
SA
Pharmaceutical Research Institute, Albany College of Pharmacy and Health Sciences, 106 New Scotland Avenue, Albany, NY 12208, USA. shaker.mousa@acphs.edu
Jeske
Walter P
WP
Fareed
Jawed
J
D054058:Acute Coronary Syndrome / Q000188:drug therapy / Q000628:therapy; D015906:Angioplasty, Balloon, Coronary; D001241:Aspirin / Q000627:therapeutic use; D017326:Clinical Trials, Phase III as Topic; D000077144:Clopidogrel; D004353:Drug Evaluation, Preclinical; D004359:Drug Therapy, Combination; D006470:Hemorrhage / Q000139:chemically induced; D006801:Humans; D007511:Ischemia / Q000517:prevention & control; D007676:Kidney Failure, Chronic / Q000378:metabolism; D010879:Piperazines / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use; D000068799:Prasugrel Hydrochloride; D058919:Purinergic P2 Receptor Antagonists; D016032:Randomized Controlled Trials as Topic; D058925:Receptors, Purinergic P2Y12; D013876:Thiophenes / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use; D013988:Ticlopidine / Q000031:analogs & derivatives / Q000627:therapeutic use
C548576:P2RY12 protein, human; D010879:Piperazines; D010975:Platelet Aggregation Inhibitors; D058919:Purinergic P2 Receptor Antagonists; D058925:Receptors, Purinergic P2Y12; D013876:Thiophenes; D000077144:Clopidogrel; D000068799:Prasugrel Hydrochloride; D013988:Ticlopidine; D001241:Aspirin